(NASDAQ: PHAT) Phathom Pharmaceuticals's forecast annual revenue growth rate of 54.49% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.39%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.6%.
Phathom Pharmaceuticals's revenue in 2026 is $204,892,000.On average, 13 Wall Street analysts forecast PHAT's revenue for 2026 to be $26,960,702,352, with the lowest PHAT revenue forecast at $25,445,339,245, and the highest PHAT revenue forecast at $28,054,156,468. On average, 13 Wall Street analysts forecast PHAT's revenue for 2027 to be $42,844,100,392, with the lowest PHAT revenue forecast at $38,221,445,356, and the highest PHAT revenue forecast at $47,834,430,371.
In 2028, PHAT is forecast to generate $60,579,431,661 in revenue, with the lowest revenue forecast at $48,294,622,220 and the highest revenue forecast at $81,191,560,154.